TELA Bio, Inc.TELAEarnings & Financial Report
TELA Bio, Inc. is a medical technology company focused on developing and commercializing innovative soft tissue repair solutions for surgical procedures. Its core product portfolio targets applications including hernia repair, abdominal wall reconstruction and other general surgery use cases, serving hospitals, ambulatory surgical centers and healthcare providers primarily across the United States and select global markets.
TELA Q4 FY2025 Key Financial Metrics
Revenue
$20.9M
Gross Profit
$13.8M
Operating Profit
$-6.6M
Net Profit
$-9.0M
Gross Margin
65.9%
Operating Margin
-31.9%
Net Margin
-43.3%
YoY Growth
18.2%
EPS
$-0.17
TELA Bio, Inc. Q4 FY2025 Financial Summary
TELA Bio, Inc. reported revenue of $20.9M (up 18.2% YoY) for Q4 FY2025, with a net profit of $-9.0M (up 1.8% YoY) (-43.3% margin). Cost of goods sold was $7.1M, operating expenses totaled $20.4M.
Key Financial Metrics
| Total Revenue | $20.9M |
|---|---|
| Net Profit | $-9.0M |
| Gross Margin | 65.9% |
| Operating Margin | -31.9% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
TELA Bio, Inc. Q4 FY2025 revenue of $20.9M breaks down across 3 segments, led by Ovitex at $13.4M (64.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Ovitex | $13.4M | 64.3% |
| Ovitex Prs | $6.8M | 32.8% |
| Other | $597.0K | 2.9% |
TELA Bio, Inc. Revenue by Segment — Quarterly Trend
TELA Bio, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Ovitex and Ovitex Prs) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Ovitex | $13.4M | — | $12.5M | — |
| Ovitex Prs | $6.8M | — | $7.3M | — |
| Other | $597.0K | — | — | — |
TELA Bio, Inc. Annual Revenue by Year
TELA Bio, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $80.3M).
TELA Bio, Inc. Quarterly Revenue & Net Profit History
TELA Bio, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $20.9M | +18.2% | $-9.0M | -43.3% |
| Q3 FY2025 | $20.7M | +9.1% | $-8.6M | -41.6% |
| Q2 FY2025 | $20.2M | +25.5% | $-9.9M | -49.1% |
| Q1 FY2025 | $18.5M | +11.5% | $-11.3M | -60.8% |
| Q4 FY2024 | $17.6M | +3.8% | $-9.2M | -52.2% |
| Q3 FY2024 | $19.0M | +25.9% | $-10.4M | -54.7% |
| Q2 FY2024 | $16.1M | +11.0% | $-12.6M | -78.3% |
| Q1 FY2024 | $16.6M | +39.4% | $-5.7M | -34.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.6M | $16.1M | $19.0M | $17.6M | $18.5M | $20.2M | $20.7M | $20.9M |
| YoY Growth | 39.4% | 11.0% | 25.9% | 3.8% | 11.5% | 25.5% | 9.1% | 18.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $71.8M | $60.2M | $53.0M | $86.6M | $77.3M | $67.5M | $61.6M | $81.4M |
| Liabilities | $57.5M | $57.3M | $59.3M | $58.1M | $59.1M | $58.4M | $60.0M | $75.1M |
| Equity | $14.4M | $2.9M | $-6.3M | $28.5M | $18.1M | $9.2M | $1.6M | $6.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-14.4M | $-10.7M | $-9.0M | $-7.5M | $-9.7M | $-7.9M | $-5.7M | $-4.9M |